Cryosite Ltd
CTE
Company Profile
Business description
Cryosite Ltd is engaged in the provision of supply chain logistics, and management of pharmaceutical products used in clinical trials. The company's operating segment includes Cord Blood and Tissue Storage and Clinical Trials and Biological Services Logistics. It generates maximum revenue from the Clinical Trials and Biological Services Logistics segment. The clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, sourcing, labeling, status management, secondary packaging, scheduled drug distribution, destruction, returns, and biological services.
Contact
13a Ferndell Street
South Granville
SydneyNSW2142
AUST: +61 288652000
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
30 June 2026
Employees
25
Stocks News & Analysis
stocks
Another incredible quarter from Microsoft
We were wrong when we thought last quarter would be hard to top.
stocks
10 best US dividend aristocrats to buy now—including a surprise outperformer
These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.
stocks
Leading ASX players in this field look materially overvalued
We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,917.10 | 81.90 | -0.91% |
| CAC 40 | 7,542.51 | 229.46 | -2.95% |
| DAX 40 | 23,440.64 | 624.83 | -2.60% |
| Dow JONES (US) | 43,452.60 | 678.38 | -1.54% |
| FTSE 100 | 9,040.42 | 92.39 | -1.01% |
| HKSE | 24,507.81 | 265.52 | -1.07% |
| NASDAQ | 20,669.12 | 453.32 | -2.15% |
| Nikkei 225 | 40,799.60 | 270.22 | -0.66% |
| NZX 50 Index | 12,729.40 | 94.34 | -0.74% |
| S&P 500 | 6,232.80 | 106.59 | -1.68% |
| S&P/ASX 200 | 8,662.00 | 80.80 | -0.92% |
| SSE Composite Index | 3,559.95 | 13.26 | -0.37% |